Compositions and Methods for Targeted Delivery of Factors
The present invention relates to compositions and methods for targeted delivery of biologically-active factors, such as cytokines, growth factors, chemotherapeutic agents, nucleic acids, and therapeutic agents. The compositions of the present invention can be used to treat diseases and pathologies in organisms. Additionally the invention relates to methods and compositions for the enhancement of an immune response in a human or animal. Such enhancement may result in stimulation or suppression of the immune response. Other compositions and methods of the present invention include vaccines and those used for reduction of the toxicity of agents.
1 - 12 . (canceled)
13 . A targeted delivery composition comprising at least one effector molecule and at least one cell-specific targeting molecule bound to a colloidal metal platform, wherein the at least one effector molecule is a nucleic acid molecule.
14 . The composition of claim 13 , wherein the nucleic acid is DNA or RNA.
15 . The composition of claim 13 , wherein the nucleic acid molecule is selected from the group consisting of, an expression vector encoding a polypeptide, an antisense oligonucleotide, a small interfering RNA (siRNA), a microRNA (miRNA), and a ribozyme.
16 . The composition of claim 13 , wherein the at least one cell-specific targeting molecule is selected from the group consisting of, Interleukin-1 (“IL-1”), Interleukin-2 (“IL-2”), Interleukin-3 (“IL-3”), Interleukin-4 (“IL-4”), Interleukin-5 (“IL-5”), Interleukin-6 (“IL-6”), Interleukin-7 (“IL-7”), Interleukin-8 (“IL-8”), Interleukin-10 (“IL-10”), Interleukin-11 (“IL-11”), Interleukin-12 (“IL-12”), Interleukin-13 (“IL-13”), Interleukin-15 (“IL-15”), Interleukin-16 (“IL-16”), Interleukin-17 (“IL-17”), Interleukin-18 (“IL-18”), lipid A, phospholipase A2, endotoxins, staphylococcal enterotoxin B, Type I Interferon, Type II Interferon, Tumor Necrosis Factor (“TNFα”), Transforming Growth Factor-β (“TGF-β”), Lymphotoxin, Migration Inhibition factor, Granulocyte-Macrophage Colony-Stimulating Factor (“CSF”), Monocyte-Macrophage CSF, Granulocyte CSF, Vascular Epithelial Growth Factor (“VEGF”), Angiogenin, Transforming Growth Factor (“TGFα”), heat shock proteins, carbohydrate moieties of blood groups, Rh factors, fibroblast growth factor, hormones, cell surface receptors, antibodies, nucleic acids, cancer cell specific antigens, tyrosinase, receptor proteins, and basic fibroblast growth factor.
17 . The composition of claim 13 , wherein the at least one cell-specific targeting molecule is a cytokine.
18 . The composition of claim 13 , wherein either the at least one effector molecule, the at least one cell-specific targeting molecule, or both are bound to the colloidal metal by an integrating molecule.
19 . The composition of claim 18 , wherein the integrating molecule is a polycationic molecule.
20 . The composition of claim 19 , wherein the polycationic molecule is selected from the group consisting of, polylysine, histones, protamine sulfate, and asialoglycoproteins.
21 . The composition of claim 18 , wherein the integrating molecule comprises members of at least one complementary binding pair.
22 . The composition of claim 21 , wherein the complementary binding pair is selected from the group consisting of, antibody/antigen, enzyme/substrate, and streptavidin/biotin.
23 . A method of delivering effector molecules to cells comprising administering the composition of any one of claims 13 - 22 to a cell or group of cells in vitro or in vivo.